Inhibitors of bone resorption, such as the bisphosphonate zoledronic acid and the fully human monoclonal antibody against the receptor activator of nuclear factor kappa B ligand (RANKL) denosumab, reduce the incidence of SREs in patients with prostate cancer and bone metastases [3, 4]. The gene discussed is TNFSF11; the disease is Familial prostate cancer.